CD69 and neoplasm: When combined with activated CTLs, it upregulated CD25 and CD69 expression on effector cells, increased the secretion of IL-2, tumor necrosis factor-α (TNF-α), and IFN-γ in vitro, and significantly curbed subcutaneous tumor growth and extended the survival time of tumor-bearing mice in vivo (48).